BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21517719)

  • 1. Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse.
    Georgakopoulos CD; Vasilakis P; Makri OE; Beredima E; Pharmakakis N
    Cutan Ocul Toxicol; 2011 Dec; 30(4):320-2. PubMed ID: 21517719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis.
    Carrasco MA
    Cornea; 2008 Jul; 27(6):743-5. PubMed ID: 18580272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
    Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR
    Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
    Benayoun Y; Adenis JP; Casse G; Forte R; Robert PY
    Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence of corneal neovascularization associated with lipid deposition after subconjunctival injection of bevacizumab.
    Chu HS; Chen TC; Hu FR; Chen WL
    Cornea; 2013 Nov; 32(11):1446-53. PubMed ID: 24055900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization.
    Qian CX; Bahar I; Levinger E; Rootman D
    Cornea; 2008 Oct; 27(9):1090-2. PubMed ID: 18812781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
    Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
    Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Subconjunctival bevacizumab for corneal neovascularization].
    Gueudry J; Richez F; Tougeron-Brousseau B; Genevois O; Muraine M
    J Fr Ophtalmol; 2010 Nov; 33(9):630-6. PubMed ID: 21035899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
    You IC; Kang IS; Lee SH; Yoon KC
    Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
    Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
    Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subconjunctival bevacizumab injection for corneal neovascularization.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Cornea; 2008 Feb; 27(2):142-7. PubMed ID: 18216566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
    Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
    Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
    Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
    Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy.
    Oh JY; Kim MK; Wee WR
    Cornea; 2009 Oct; 28(9):1070-3. PubMed ID: 19724199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Corneal neovascularisation treatments compared: Subconjunctival bevacizumab injections and/or photodynamic therapy].
    Hamdan J; Boulze M; Aziz A; Alessi G; Hoffart L
    J Fr Ophtalmol; 2015 Dec; 38(10):924-33. PubMed ID: 26522892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
    Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
    Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP; Bhat PV; Foster CS
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose topical bevacizumab for corneal neovascularization.
    Waisbourd M; Levinger E; Varssano D; Moisseiev E; Zayit-Soudri S; Barak A; Loewenstein A; Barequet I
    Pharmacology; 2013; 92(5-6):310-4. PubMed ID: 24335191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.